• DOI:10.1007/BF00280060
• Corpus ID: 626920

Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals

@article{Sica2004PharmacokineticsAP,
  title={Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals},
  author={Domenic A. Sica and Thomas J. Comstock and J. Davis and L Manning and Robert Powell and Armen P. Melikian and George Joseph Wright},
  journal={European Journal of Clinical Pharmacology},
  year={2004},
  volume={39},
  pages={193-194}
}

• D. Sica, T. Comstock, +4 authors G. Wright
• Published 2004
• Medicine, Biology
• European Journal of Clinical Pharmacology

SummaryWe determined plasma methocarbamol concentrations over 24 h following a 1.5 g methocarbamol dose (off-dialysis day) to 8 chronic haemodialysis patients and compared these results to those from 17 healthy male volunteers.The harmonic mean elimination half-life was similar between the two groups, 1.24 and 1.14 h, respectively. tmax and the weight-adjusted Cmax were 1.1 h and 27.0 mg · m−1 for haemodialysis patients and 1.1 and 23.1 mg · l−1 for normals. Relative systemic availability was assessed by comparing weight-normalized AUC × k10 products.These results indicate no significant differences with respect to methocarbamol absorption, with the relative systemic availability in patients being 113%.These data suggest that absorption and elimination of methocarbamol is similar between normal subjects and patients undergoing maintenance haemodialysis.